Therefore, glucocorticoids are thought to directly affect bone metabolism. The synthetic glucocorticoid dexamethasone induces osteoblastic differentiation and is often included in the osteogenic medium [7] . However, glucocorticoids are also known to induce apoptosis of osteoblasts and osteocytes, which is consistent with clinical glucocorticoid-induced osteoporosis [8] . Thus, glucocorticoids have variable effects on osteoblastic cells [9] .
SaOS2 is an osteoblastic cell line which is often used for in vitro analysis of osteoblastic cells. In SaOS2 cells, stimulation with glucocorticoids suppresses growth and promotes activity of alkaline phosphatase, a differentiation marker of the osteoblasts [10, 11] . In this study, we performed a comprehensive mi-NheI and ClaI, and ligated into pTRE2puro vector.
Cell culture
SaOS2 cells and MG63 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS), at 37ºC under 5% CO 2 . SaOS2 cells and MG63 cells were cultured in phenol red-free DMEM with 5% charcoal/dextran-treated FCS for at least 24 h prior to dexamethasone (SIGMA, St. Louis, MO, USA), or vehicle (0.1% ethanol) treatment.
Microarray analysis
SaOS2 cells were incubated with dexamethasone (10 -8 M) or vehicle for 6 h, and then, total RNA was extracted from the cells using a ToTALLY RNA Kit (Ambion). cDNA was synthesized from 5 µg of total RNA using a T7 promoter primer and amplified to generate cyanine 3-or cyanine 5-labeled cRNA using a fluorescent linear amplification kit (Agilent Technology, Palo Alto, CA). cDNA derived from dexamethasone-treated cells and vehicle-treated cells were labeled with cyanine 5 and cyanine 3, respectively. Hybridization solution was applied to the human 44K microarray kit (Agilent Technology), and incubated at 60°C for 17 h. After hybridization, the microarray was scanned with the GenePix 4000B scanner (Molecular Devices, Union City, CA).
Quantitative real-time polymerase chain reaction analysis
Total RNA was isolated using the TOTALLY RNA kit (Ambion). First strand cDNA was generated by using PrimeScript RT reagent Kit (TAKARA). mRNAs were quantified by real-time polymerase chain reaction (PCR) using SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, USA) and the 7500 Fast Real-Time PCR system (Applied Biosystems). The evaluation of relative differences in the amount of the PCR products between the treatment groups was carried out using 18S rRNA as an internal control. The primer sequences for PCR amplification are listed in Table 1 .
croarray analysis of glucocorticoid-induced genes in SaOS2 cells. Several genes expressed in osteoblasts or other tissues were shown to be induced by glucocorticoids. We here report that one of the glucocorticoid-induced genes was TRIM63, an E3 ubiquitin ligase whose function in bone tissue had been largely unknown.
Materials and Methods

Plasmids
Expression vector of TRIM63 was generated by subcloning TRIM63 cDNA fragment derived from dexamethasone-treated SaOS2 cells into pTRE2puro vector (Invitrogen, Carlsbad, CA). SaOS2 cells were incubated with dexamethasone (10 -8 M) for 6 h, and then, total RNA was extracted from the cells using a ToTALLY RNA Kit (Ambion, Austin, TX). First strand cDNA generated by using PrimeScript RT reagent Kit (TAKARA, Kyoto, Japan) was used as a template in the following PCR. Flag epitope-tagged TRIM63 construct was generated by amplifying the coding region of human TRIM63 by PCR using prim ers 5'-CGACGCGTACCATGGACTACAAGGAC GACGATGACAAGGATTATAAGTCGAGCCTGAT CCAG-3' and 5'-GGATATCACTGGTGTCCTTCTTC CTTCC-3'. This resulted in a fragment with a MluI site (underlined), a sequence encoding the FLAG epitope, TRIM63 sequence, followed by a termination codon and an EcoRV site (underlined). This fragment was then digested with MluI and EcoRV, and ligated into pTRE2puro. This vector was used as a template for the following PCR. An HA and Flag epitopetagged TRIM63 construct was generated by PCR with primers 5'-CTAGCTAGCAGGATGGCCTACCCCTA CGACGTGCCCGACTACGCCCTCGATGGAGGAG ACTACAAGGACGACGATGACAA-3' and 5'-CCATC GATCACTGGTGTCCTTCTTCCTTCC-3'. This resulted in a fragment with a NheI site (underlined), a sequence encoding the HA epitope, Flag epitope, TRIM63 sequence, followed by a termination codon and a ClaI site (underlined). This fragment was then digested with table 1. List of gene-specific primers for quantitative real-time polymerase chain reaction.
Gene
Forward primer (5' to 3') Reverse primer (5' to 3'
GGAGCCACCTTCCTCTTGAC GTCAATGGCTCTCAGGGCGT 18S rRNA AAGCATTTGCCAAGAATGTTTT TTAAGTTTCAGCTTTGCAACCA 1,000 cells/well. The viable cell number was quantified using the tetrazolium salt, WST-8 (Nakalai Tesque, Kyoto, Japan) that could be converted to a water-soluble formazan by metabolically active cells. Spectrophotometric absorbance for formazan dye was measured at 450 nm, with absorbance at 655 nm considered as the reference value using microplate reader (BIO-RAD, Hercules, CA, USA). A two-way ANOVA was used to compare the four clones with main factors of TRIM63 overexpression and the clone number.
Osteoblastic differentiation
For osteoblastic differentiation, SaOS2 cells were cultured in the medium containing 20 ng/mL bone morphogenetic protein 9 (BMP-9) (R&D systems, Minneapolis, MN). Difference in levels of alkaline phosphatase (ALP) mRNA was analyzed by a twoway ANOVA with main factors of TRIM63 overexpression and the clone number.
results
Dexamethasone-induced genes in SaOS2 cells
For a comprehensive analysis of the effect of glucocorticoids on osteoblasts, SaOS2 human osteoblastic cells were stimulated by 10 -8 M dexamethasone for 6 hours. The mRNA was extracted and microarray anal-
Generation of stable cell lines
Transfection of the HA and Flag epitope-tagged TRIM63 or empty pTRE2puro vector was performed using FuGENE 6 (Roche, Castle Hill, Australia) according to the manufacturer's instructions. To establish stable transfectants, SaOS2 clones were selected using puromycin (Invitrogen) at a concentration of 1 µg/mL. Screening of the clones was done by Immunoblotting using anti-Flag M2 monoclonal antibody (SIGMA).
Immunoblotting
Immunoblotting was performed as described previously [12] . The lysate of each SaOS2 clone (20 μg) was applied to SDS-PAGE. The gel was transferred on to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Anti-Flag M2 monoclonal antibody (SIGMA) (1:5000) and anti-α-tubulin monoclonal antibody (SIGMA) (1:10000) were used as the primary antibodies. HRP-conjugated anti-mouse antibody (Amersham Pharmacia Biotech, Arlington Heights, IL, USA) (1:5000) was used as the secondary antibody. Immunoreactive proteins were visualized with the Western Lighting ECL kit (Perkin Elmer, Boston, MA, USA).
Cell proliferation assay
Cells were seeded in 96-well plates at a density of since, to our knowledge, this gene had not been hitherto reported to be expressed in osteoblasts. Induction of glucocorticoid-responsive genes identified by microarray analysis was validated with the following 3 concentrations of dexamethasone, including the pharmacological dose: 10 -8 M, 10 -7 M and 10 -6 M. The induction of mRNA was confirmed in all genes tested in both physiological dose and pharmacological dose of dexamethasone ( Fig. 1A-1D ).
To exclude the possibility that the induction of ysis was performed to compare glucocorticoid-stimulated samples with control samples stimulated by vehicle. The 20 genes induced in highest ratio are listed in Table 2 . Among these 20 genes, dual-specificity phosphatase 1 (DUSP1), CCAAT/enhancer binding protein δ (C/EBPδ) and period homolog 1 (Per1) were selected for further validation with quantitative real-time PCR, considering their potential involvement in osteoblastic differentiation or proliferation. TRIM63 was also subjected to the validation with quantitative real-time PCR dependent vector clones (vec#1 and #2) were established, and their levels of TRIM63 expression were confirmed by quantitative real-time PCR and immunoblotting ( Fig. 2A) .
Growth suppression in TRIM63-overexpressing SaOS2 cells
To evaluate the effect of TRIM63 on proliferation, we performed growth assays using 2 TRIM63overexpressing clones and 2 vector clones. The TRIM63-overexpressing SaOS2 clones and the vector clones were seeded at a density of 1000 cells/well and cultured in DMEM with 10% FCS. The cell growth was assayed using the tetrazolium salt WST-8 on day 0 and on day 2. The relative absorbance of each clone on day 2 is shown in Figure 2B . The proliferation of TRIM63-overexpressing clones was significantly less than that of the vector clones.
TRIM63 by dexamethasone was a phenomenon specific to SaOS2 cells, another human osteoblastic cell line MG63 was used as well. Dexamethasone (10 -7 M) elicited the expression of C/EBPδ (Fig. 1E ) and TRIM63 (Fig. 1F ) in MG63 cells, though TRIM63 expression was lower as compared with that in SaOS2 cells.
Establishment of SaOS2 cells overexpressing TRIM63
Among the validated dexamethasone-responsive genes in human osteoblastic cells, TRIM63 was chosen for further functional analyses. TRIM63, also called muscle-specific ring finger protein 1 (Murf1), had been reported to be an E3 ubiquitin ligase expressed mainly in muscular tissue and related to muscle atrophy [13] . The functions in other tissues were largely unknown.
Two independent clones stably overexpressing exogenous TRIM63 (TRIM63#1 and #2) and two in- deficient mice displayed high bone mass, which means Per1 has a suppressive role in bone formation. This is considered to be due to suppression of AP-1 and Myc by Per1, which results in suppressed proliferation. The findings of this study indicate TRIM63 is induced by glucocorticoids in osteoblastic cells. TRIM63, also called MuRF1, is expressed mainly in muscular tissue. TRIM63 was originally known as a protein induced during muscle atrophy caused by multiple causes such as immobilization and denervation [13] . TRIM63 has a RING finger domain at its N-terminus and functions as an E3 ubiquitin ligase in muscular tissue. In skeletal muscle, TRIM63 is shown to be involved in the degradation of myosin heavy chain [21] , whereas in cardiac muscle it is involved in the degradation of troponin I [22] . TRIM63 is shown to be induced by dexamethasone in skeletal muscle [21] , indicating potential role of this gene in steroidinduced muscle atrophy. The functions of TRIM63 in other tissues have been largely unknown.
Present results suggest that TRIM63 suppressed the proliferation and promoted the differentiation of osteoblastic cells. The mechanism of these effects may well be explained by its ubiquitin ligase activity. Considering that myosin and troponin I are not expressed in osteoblastic cells [23, 24] , it can be inferred
Increase of the osteoblastic differentiation marker, ALP, in TRIM63-overexpressing SaOS2 cells
We then focused on the effects of TRIM63 on differentiation of SaOS2 cells. The TRIM63overexpressing clones and the vector clones were treated with 20 ng/mL BMP9 for 4 days and mRNA of ALP was evaluated by quantitative real-time PCR. The expression level of ALP was higher in TRIM63overexpressing clones than in the vector clones (Fig 3) , suggesting that TRIM63 promoted the differentiation of SaOS2 cells.
discussion
In the present study, we showed four genes-DUSP1, C/EBPδ, Per1 and TRIM63-were induced by a synthetic glucocorticoid in a human osteoblastic cell line, SaOS2. We also suggested that TRIM63 suppressed the proliferation and promoted the differentiation of SaOS2 cells.
Microarray analysis revealed that DUSP1 was the most prominently induced gene. DUSP1 is a phosphatase that downregulates mitogen-activated protein kinase (MAPK) signaling. Induction of DUSP1 by glucocorticoids has been reported in macrophages [14] . Considering that MAPK signaling is involved in cell proliferation, it can be inferred that induction of DUSP1 can suppress the proliferation of osteoblastic cells. Thus, induction of DUSP1 may contribute to the suppression of osteoblastic activity by glucocorticoids by decreasing the number of osteoblasts.
C/EBPδ, a gene that we identified to be induced by dexamethasone, is reported to be involved in adipocytic differentiation, as in the case with the gene encoding the CCAAT/enhancer binding protein family members C/EBPα and C/EBPβ [15, 16] . C/EBPδ could be responsible for the adipocytic, rather than osteoblastic, differentiation of osteoblastic progenitor cells. C/ EBPδ also plays a role in glucocorticoid-dependent transcriptional repression of insulin-like growth factor I (IGF-I) in primary osteoblasts [17] . Since IGF-I is required for proliferation of osteoblasts [18] , glucocorticoid-dependent upregulation of C/EBPδ may lead to the suppression of osteoblastic proliferation.
Upregulation of Per1 by glucocorticoids has been reported in several tissues [19] . Per1 is originally known as a clock gene. On the other hand, relationship between Per1 and bone metabolism was elucidated by analysis of Per1-deficient mice [20] . Per1- in the osteoclasts and affects osteoblastic function.
In the present study, we found TRIM63 as a candidate gene playing a role in the glucocorticoid-induced differentiation of osteoblasts. In addition, TRIM63 might be involved in physiological differentiation process of osteoblasts. Future studies concerning the regulation of TRIM63 in differentiating stages of osteoblasts and the bone phenotypes in TRIM63-deficient mice would be required to clarify this possibility.
In conclusion, we identified several glucocorticoidinduced genes in osteoblasts by comprehensive microarray analysis. These genes encoded transcription factors, phosphatases and E3 ubiquitin ligases, indicating that glucocorticoids affect multiple stages of protein regulation including transcriptional control, posttranscriptional modification, and degradation. These genes may be involved in physiological bone function or pathophysiology of glucocorticoid-induced osteoporosis. Further functional analyses will be required to understand the detailed mechanism of action of glucocorticoids on osteoblasts and to explain the discrepancy between the results of in vitro and in vivo experiments. that other osteoblast-specific target proteins may exist. Purification of TRIM63 binding protein would help to identify the candidate substrates of TRIM63.
The effect of TRIM63 overexpression is consistent with previous reports on the global effects of glucocorticoids on human bone marrow stromal cells and SaOS2 cells [7, [10] [11] . According to the previous report, glucocorticoids suppressed the proliferation and promoted osteoblastic differentiation. However, some in vivo experiments showed that glucocorticoids suppressed osteoblastic function.
One possible explanation for this discrepancy is that glucocorticoids induce genes promoting osteoblastic differentiation as well as those suppressing osteoblastic differentiation and the balance between the expression levels of these genes varies by condition. For example, among the glucocorticoid-induced genes identified in the present study, C/EBPδ belongs to suppressive genes and TRIM63 belongs to promoting gene. To evaluate the osteoblastic differentiation more definitely, examination of ALP activity and induction of other osteoblastic markers, such as Runx2 and Osterix, may be informative. Knockdown experiments utilizing TRIM63 siRNA would help to estimate the contribution of TRIM63 in the effects of glucocorticoids on osteoblasts.
Another factor to be considered is the effect of glucocorticoids on osteoclasts. Macrophage-specific ablation of GRα, which resulted in the lack of GRα in bone marrow macrophages and osteoclasts in bone tissue, exerted protective effect on glucocorticoid-induced osteoporosis in vivo [6] . This means functional GRα exists references
